Fig 2: Effect of NAMPT and FK866 on mitochodrial activity in KGN cells. Mitochondrial activity in NAMPT- (B, B’, and B”) and FK866- (D, D’, and D”) treated KGN cells. Control 1 (A, A’, and A”) represents cells incubated with medium only, while control 2 (C, C’, and C”) represents cells incubated with medium plus DMSO (0.01%). Such distinctions reflect real experimental conditions. Treatment with visfatin (NAMPT) increased red fluorescence (representing active mitochondria with a high potential) (B’); therefore, red fluorescence is predominant in the merged image (B”). Treatment with the visfatin inhibitor FK866 decreased red fluorescence (representing active mitochondria) (D’) and increased green fluorescence emitted from inactive organelles (D); therefore, green fluorescence is predominant in the merged image (D”). Scale bar: 100 μm

Fig 3: Basal levels of visfatin in non-cancer and cancer ovarian cell lines. Basal expression of mRNA encoding visfatin (NAMPT), and visfatin synthesis levels, in human ovarian non-cancer epithelial (HOSEpiC) and granulosa (HGrC1) ovarian cell lines (a, d), and in epithelial ovarian cancer cell lines (OVCAR-3) and (SKOV-3) (b, e), compared with HOSEpiC; and in ovarian granulosa tumor (KGN) cells compared with HGrC1 (c, f). Expression of NAMPT mRNA in HOSEpiC cells was set to 1.0 (RQ = relative quantity) (a, b), and expression of NAMPT mRNA in HGrC1 cells was set to RQ = 1.0. c Each bar represents the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001